Livzon Pharmaceutical Group reports November 2025 securities changes

Livzon Pharmaceutical Group has confirmed its share capital and issued shares as of November 30, 2025. The company's H-share registered share capital remains at RMB 299,807,117, with 299,807,117 shares outstanding. For its A-shares, the registered share capital stands at RMB 604,293,313, representing 604,293,313 shares. The total registered share capital for the company across both share classes at the end of November 2025 is RMB 904,100,430.

The report indicates no increases or decreases in either H-shares or A-shares during the month of November, maintaining the previously reported figures. However, the company noted a proposed repurchase of -16,193,259 A-shares, which are intended for cancellation, with an event date of December 24, 2024. This repurchase would impact the issued A-shares upon completion.

The company has confirmed that all necessary regulatory approvals and compliance requirements for securities issuance and transfers have been met. All shares are reported to be identical in rights and entitlements, and all legal documentation has been duly filed.